Tysabri Should Be Used As Monotherapy Only, FDA Urges
This article was originally published in The Pink Sheet Daily
Executive Summary
Concomitant use with immunosuppressants may be risk factor for PML.
You may also be interested in...
Tysabri Risk Management Plan Needs Strengthening, FDA Says
Agency calls for additional restrictions in prescribing, dispensing and use.